Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

PCI Biotech Holding ASA (PCIB) NOK3

Sell:34.50 NOK Buy:35.00 NOK Change: 2.50 NOK (7.81%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:34.50 NOK
Buy:35.00 NOK
Change: 2.50 NOK (7.81%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
Sell:34.50 NOK
Buy:35.00 NOK
Change: 2.50 NOK (7.81%)
Market closed |  Prices as at close on 15 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PCI Biotech Holding ASA is a Norway-based company engaged in the biotechnology sector. Its activities are focused on the commercialization of a patented photochemical drug delivery technology for use in the localized cancer treatment. The Company’s products are based on the Photochemical Internalization (PCI) technology for light-directed drug delivery, used to enhance the effect of drugs by targeted illumination of the diseased areas of the body. It focuses primarily on the drug candidate Amphinex, developed for treatment of head and neck cancer and bile duct cancer, as well as on the development of PCI for vaccination. As of December 31, 2011, it had a wholly owned subsidiary PCI Biotech AS and an affiliate PCIO Biotech Utibu, located in Iceland.

Contact details

Address:
Ullernchauseen 64
OSLO
0379
Norway
Telephone:
+47 (67) 115400
Website:
www.pcibiotech.no/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PCIB
ISIN:
NO0010405640
Market cap:
1.19 billion NOK
Shares in issue:
37.23 million
Sector:
Biotechnology
Exchange:
Oslo Stock Exchange
Country:
Norway
Currency:
Norwegian Krone
Indices:
Oslo All Share Index

Key personnel

  • Hans Bohn
    Chairman of the Board
  • Per Walday
    Chief Executive Officer
  • Ronny Skuggedal
    Chief Financial Officer
  • Anders Hogset
    Chief Scientific Officer
  • Hans Olivecrona
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.